ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Up 72.6% in January

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 44,222 shares, an increase of 72.6% from the December 31st total of 25,624 shares. Based on an average daily volume of 54,403 shares, the short-interest ratio is presently 0.8 days. Currently, 1.7% of the shares of the stock are sold short. Currently, 1.7% of the shares of the stock are sold short. Based on an average daily volume of 54,403 shares, the short-interest ratio is presently 0.8 days.

ALPS Medical Breakthroughs ETF Stock Down 2.1%

NYSEARCA:SBIO traded down $1.11 during trading hours on Friday, reaching $51.25. 36,268 shares of the company’s stock were exchanged, compared to its average volume of 46,683. The company has a 50-day moving average of $50.97 and a 200 day moving average of $42.84. ALPS Medical Breakthroughs ETF has a 1-year low of $22.33 and a 1-year high of $54.79.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp purchased a new position in ALPS Medical Breakthroughs ETF during the 1st quarter valued at about $782,000. Moran Wealth Management LLC purchased a new position in shares of ALPS Medical Breakthroughs ETF during the second quarter worth about $300,000. Strategic Financial Services Inc. raised its holdings in ALPS Medical Breakthroughs ETF by 97.8% during the second quarter. Strategic Financial Services Inc. now owns 38,032 shares of the company’s stock worth $1,144,000 after purchasing an additional 18,807 shares during the last quarter. Ally Invest Advisors Inc. acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the second quarter worth approximately $200,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the second quarter valued at about $82,000.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.